Objective To explore the economic value of Shenling Baizhu powder in treatment of sarcopenia in older men by using cost-utility analysis.

Methods A total of 280 older men with sarcopenia were divided into a intervention group (140 cases) and a control group (140 cases). Patients in the two groups were given nutrition sports treatment, patients in the intervention group were given Shenling Baizhu powder on the basis of nutrition sports treatment, patients in both groups were followed up for 24 weeks. From the perspective of healthcare, by establishing a decision tree model and using the TreeAge Pro 2011, cost-utility analysis was performed for the two treatment schemes. The un-certainty of the results was evaluated with sensitivity analysis.

Results  Compared with the control group, the intervention group had higher cost ( 5 019.46 yuan vs. 4 864.57 yuan ) and higher utility [0.90357 quality adjusted life years (QALYs) vs. 0.89430 QALYs]. The incremental cost-utility ratio value was 16 712.05 yuan/QALY, which was lower than the willing to pay threshold. The results of sensitivity analysis were consistent with those of cost-utility analysis.

Conclusion  Compared with using the nutrition sports treatment alone, the use of Shenling Baizhu powder combined with nutrition sports treatment in elderly male sarcopenia patients is more cost-utility.

1.Chang CD, Wu JS, Mhuircheartaigh JN, et al. Effect of sarcopenia on clinical and surgical outcome in elderly patients with proximal femur fractures[J]. Skeletal Radiol, 2018, 47(6): 771-777. DOI: 10.1007/s00256-017-2848-6.

2.孙建琴, 张坚, 常翠青, 等. 肌肉衰减综合征营养与运动干预中国专家共识(节录)[J]. 营养学报, 2015, 37(4): 320-324. [Sun JQ, Zhang J, Chang CQ, et al. Chinese experts consensus on  nutrition sports interven-tion in sarcopenia[J]. Acta Nutrimenta Sinica, 2015, 37(4): 320-324.] DOI: 10.13325/j.cnki.acta.nutr.sin.2015.04.006.

3.王琴, 张彬, 林萍, 等. 参苓白术散治疗肌少症患者的临床疗效观察[J]. 中华危重病急救医学, 2021, 33(8): 994-998. [Wang Q, Zhang B, Lin P, et al. Clinical effect of Shenling Baizhu San on patients sarcopenia[J]. Chinese Critical Care Medicine, 2021, 33(8): 994-998.] DOI: 10.3760/cma.j.cn121430-20210218-00250.

4.卢广英, 邢训颜, 王嘉昀, 等. 经典名方参苓白术散的研究进展及质量标志物的预测分析[J]. 中国中药杂志, 2022,47(19): 5171-5181. [Lu GY, Xing XY, Wang JY, et al. Research progress of Shenling Baizhu San and predictive analysis on quality markers[J]. China Journal of Chinese Materia Medica, 2022, 47(19): 5171-5181.] DOI: 10.19540/j.cnki.cjcmm.20220421.201.

5.Chen LK, Woo J, Assantachai P, et al. Asian working group for sarcopenia: 2019 consensus update on sarcopenia diagnosis and treatment[J]. J Am Med Dir Assoc, 2020, 21(3): 300-307.e2. DOI: 10.1016/j.jamda.2019.12.012.

6.郑筱萸，主编. 中药新药临床研究指导原则[M]. 北京: 中国医药科技出版社, 2002: 361-377.

7.孙利华, 主编. 药物经济学, 第3版[M]. 北京: 中国医药科技出版社, 2016: 1-392.

8.吴久鸿, 主编. 药物经济学[M]. 北京: 高等教育出版社, 2017: 1-221.

9.河北省药品集中采购平台[EB/OL]. (2021-02-26)[2022-09-06]. http://60.205.165.231/deal/purchase/toaction.

10.Go SW, Cha YH, Lee JA, et al. Association between sarcopenia, bone density, and health-related quality of life in Korean men[J]. Korean J Fam Med, 2013, 34(4): 281-288. DOI:10.4082/kjfm.2013.34.4.281.

11.刘国强, 高胜男, 郭素景, 等. 吲哚布芬和低分子肝素预防髋关节置换术后深静脉血栓的成本-效果分析[J]. 中国药师, 2020, 23(7): 1379-1382. [Liu GQ, Gao SN, Guo SJ, et al. Cost-effectiveness analysis of indobufen and low molecular weight heparin in preventing deep vein thrombosis after hip replacement[J]. China Pharmacist, 2020, 23(7): 1379-1382.] DOI: 10.3969/j.issn.1008-049X.2020.07.031.

12.刘国恩, 主编. 中国药物经济学评价指南2020: 中英双语版[M].  北京: 中国市场出版社, 2020: 41-47.

13.国家统计局. 2020年国民经济和社会发展统计公报[R/OL].（2021-02-28）[2022-09-06]. http://www.stats.gov.cn/tjsj/zxfb/202102/t20210227_1814154.html.

14.谭重庆, 彭六保, 曾小慧, 等. 药物经济学评价中敏感度分析的参数分布[J]. 中国新药与临床杂志, 2015, 34(12): 961-964. [Tan CQ, Peng LB, Zeng XH, et al. Distributions for parameters in sensitivity analysis of phamacoeconomics evaluation[J]. Chinese Journal of New Drugs and Clinical Remedies, 2015, 34(12): 961-964.] DOI: 10.14109/j.cnki.xyylc.2015.12.015.

15.朱晓晨, 陈彦瑾, 韩晟. 哌罗匹隆治疗精神分裂症的药物经济学评价——基于主要不良事件的研究[J]. 中国药房, 2021, 32(10): 1252-1256. [Zhu XC, Chen YJ, Han S. Pharmacoeconomic evaluation of perospirone in the treatment of schizo-phrenia: a study based on major adverse events[J]. China Pharmacy, 2021, 32(10): 1252-1256.] DOI: 10.6039/j.issn.1001-0408.2021.10.16.

16.蒋芳, 张晓黎, 蒋玲. 肌肉减少症对50岁以上男性骨密度及生命质量的影响[J]. 中华骨质疏松和骨矿盐疾病杂志，2017,10(5): 456-461. [Jiang F, Zhang XL, Jiang L. Effects of sarcopenia on bone mineral density and health-related quality of life of men over 50 years old[J]. Chinese Journal of Osteoporosis and Bone Mineral Research, 2017, 10(5): 456-461.] DOI: 10.3969/j.issn.1674-2591.2017.05.005.

17.臧华龙, 泰学祥, 翁敏. 口服营养补充剂对维持性血液透析病人肌少症及生存质量的影响[J]. 肠外与肠内营养, 2018, 25(6): 349-354. [Zang HL, Tai XX, Weng M. Effects of oral nutritional supplements on sarcopenia and quality of life in maintenance hemodialysis patients[J]. Parenteral & Enteral Nutrition, 2018, 25(6): 349-354.] DOI: 10.16151/j.1007-810x.2018.11.007.

18.陈欣. 补中益气汤联合八段锦辅以强化营养支持治疗老年肌少症效果观察[J]. 实用中医药杂志, 2022, 38(2): 179-180. [Chen X. Effect of Buzhong Yiqi decoction and intensive nutritional support therapy in sarco-penia in older[J]. Journal of Practical Traditional Chinese Medicine, 2022, 38(2): 179-180.] https://d.wanfangdata.com.cn/periodical/ChlQZXJpb2RpY2FsQ0hJTmV3UzIwMjMwMTEyEhBzeXp5eXp6MjAyMjAyMDA5GghoMjRwNHBzdg%3D%3D.

19.任朋, 杨秋安. 营养干预对食管癌同步放化疗期间骨骼肌的影响[J]. 中国医学科学院学报, 2020, 42(5): 610-618. [Ren P, Yang QA. Effect of nutrition intervention on skeletal muscle during concurrent chemoradio-therapy for esophageal cancer[J]. Acta Academiae Medicinae Sinicae, 2020, 42(5): 610-618.] DOI: 10.3881/j.issn.1000-503X.12941.

20.梁清月, 王仲, 刘戎, 等. 加减八珍汤联合营养支持治疗老年骨骼肌减少症疗效观察[J]. 中国中西医结合杂志, 2019, 39(7): 821-825. [Liang QY, Wang Z, Liu R, et al. Clinical effect of Bazhen decoction plus or minus nutri-tion support on elderly sarcopenia[J]. Chinese Journal of Integrated Traditional and Western Medicine, 2019, 39(7): 821-825.] DOI: 10.7661/j.cjim.20190404.006.

21.杨静, 陈鹏. 经筋推拿改善老年肌少症患者下肢肌肉力量与质量临床观察[J]. 浙江中医杂志, 2016, 51(10): 753. [Yang J, Chen P. Clinical effect of massage through tendons in improvement the muscle strength and quality of lower limb in sarcopenia in older[J]. Zhejiang Journal of Traditional Chinese Medicine, 2016, 51(10): 753] DOI: 10.13633/j.cnki.zjtcm.2016.10.035.

22.鞠宝兆，陈庚. 《内经》有关神经肌肉疾病名义辨析[J]. 长春中医药大学学报, 2007, 23(6): 4-5. [Ju BZ, Chen G. Discrimination on terms related to neuromusculal diseases found in Internal Classic[J]. Journal of Changchun University of Chinese Medicine, 2007, 23(6): 4-5.] DOI: 10.3969/j.issn.1007-4813.2007.06.003.

23.温春瑜, 陈颖颖, 彭鹏, 等. 补中益气汤加减辅助治疗老年肌少症的临床疗效观察[J]. 实用中西医结合临床, 2018, 18(7): 72-73. [Wen CY, Chen YY, Peng P, et al. Clinical effect of Buzhong Yiqi decoction plus or minus adjuvant therapy on elderly sarcopenia[J]. Practical Clinical Journal of Integrated Traditional Chinese and Western Medicine, 2018, 18(7): 72-73.] DOI: 10.13638/j.issn.1671-4040.2018.07.036.

24.吴心语, 张朝明, 游小兰, 等. IGF-1在2型糖尿病肾病中的表达及作用[J]. 实用检验医师杂志, 2018, 10(3): 164-167, 172.[Wu XY, Zhang CM, You XL, et al. Expression and application of insulin-like growth factor-1 in type 2 diabetic nephropathy[J]. Chinese Journal of Clinical Pathologist, 2018, 10(3): 164-167, 172.] DOI: 10.3969/j.issn.1674-7151.2018.03.012.

25.彭俊华, 葛锁华, 张欢妍, 等. 参苓白术散联合二甲双胍对2型糖尿病肥胖者miR-146a、GLP-1及血脂的影响[J]. 天津医药, 2021, 49(2): 203-207. [Peng JH, Ge SH, Zhang HY, et al. The influence of Shenling Baizhu powder and metformin on miR-146a, GLP-1 andblood lipid in type 2 diabetes mellitus obesity[J]. Tianjin Medi-cal Journal, 2021, 49(2): 203-207.] DOI: 10.11958/20200931.